Since the first report of a new pneumonia disease in December 2019 (Wuhan, China) the WHO reported more than 148 million confirmed cases and 3.1 million losses globally up to now. The causative agent of COVID-19 (SARS-CoV-2) has spread worldwide, resulting in a pandemic of unprecedented magnitude. To date, several clinically safe and efficient vaccines (e.g., Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca COVID-19 vaccines) as well as drugs for emergency use have been approved. However, increasing numbers of SARS-Cov-2 variants make it imminent to identify an alternative way to treat SARS-CoV-2 infections. A well-known strategy to identify molecules with inhibitory potential against SARS-CoV-2 proteins is repurposing clinically developed drugs, e.g., antiparasitic drugs. The results described in this study demonstrated the inhibitory potential of quinacrine and suramin against SARS-CoV-2 main protease (3CL pro ). Quinacrine and suramin molecules presented a competitive and noncompetitive inhibition mode, respectively, with IC 50 values in the low micromolar range. Surface plasmon resonance (SPR) experiments demonstrated that quinacrine and suramin alone possessed a moderate or weak affinity with SARS-CoV-2 3CL pro but suramin binding increased quinacrine interaction by around a factor of eight. Using docking and molecular dynamics simulations, we identified a possible binding mode and the amino acids involved in these interactions. Our results suggested that suramin, in combination with quinacrine, showed promising synergistic efficacy to inhibit SARS-CoV-2 3CL pro . We suppose that the identification of effective, synergistic drug combinations could lead to the design of better treatments for the COVID-19 disease and repurposable drug candidates offer fast therapeutic breakthroughs, mainly in a pandemic moment.
【저자키워드】 COVID-19, SARS-CoV-2, main protease, quinacrine, Suramin, Repurposing approved drugs, 3CLpro, 【초록키워드】 Treatment, Efficacy, Vaccine, pandemic, Pneumonia, variant, drugs, drug, 3CL pro, docking, surface plasmon resonance, SPR, SARS-CoV-2 main protease, antiparasitic, COVID-19 disease, Spread, COVID-19 vaccines, therapeutic, experiment, molecular, disease, moderate, SARS-CoV-2 infections, Pfizer-BioNTech, interactions, AstraZeneca, Moderna, binding, Emergency use, Amino acid, Combination, Interaction, Safe, confirmed case, drug combination, treat, drug candidate, SARS-CoV-2 protein, offer, Johnson & Johnson, inhibitory, effective, synergistic, Wuhan, China, resulting, described, identify, involved, reported, clinically, approved, eight, demonstrated, suggested, magnitude, the WHO, inhibit SARS-CoV-2, 【제목키워드】 drug, 3CL pro,